Patents by Inventor Asae Shintani

Asae Shintani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Zika vaccines and immunogenic compositions, and methods of using the same
    Patent number: 11975062
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 7, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Asae Shintani, Holli Giebler, James Gifford, Mark Lyons, Sushma Kommareddy, Tatsuki Satou
  • Method for inactivating zika virus and for determining the completeness of inactivation
    Patent number: 11964008
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: April 23, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
    Publication number: 20240024454
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Nao Ogasawara, Masafumi Misaki, Satoshi Adachi, Sushma Kommareddy
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20230398199
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 14, 2023
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Asae SHINTANI, Holli GIEBLER, James GIFFORD, Mark LYONS, Sushma KOMMAREDDY, Tatsuki SATOU
  • METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION
    Publication number: 20230145065
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Application
    Filed: September 13, 2022
    Publication date: May 11, 2023
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • Method for inactivating Zika virus and for determining the completeness of inactivation
    Patent number: 11478541
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford
  • METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
    Publication number: 20210403879
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 30, 2021
    Inventors: Jill A LIVENGOOD, Holli GIEBLER, Hansi DEAN, Tatsuki SATOU, Raman RAO, Jackie MARKS, Mark LYONS, Asae SHINTANI, James GIFFORD, Nao OGASAWARA, Masafumi MISAKI, Satoshi ADACHI
  • METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION
    Publication number: 20210177959
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: Jill A. LIVENGOOD, Holli GIEBLER, Hansi DEAN, Tatsuki SATOU, Raman RAO, Jackie MARKS, Mark LYONS, Asae SHINTANI, Jamie GIFFORD
  • TGF-? superfamily production/secretion promoter
    Patent number: 7498352
    Abstract: The present invention provides a TGF-? superfamily production/secretion promoter comprising a compound represented by the formula wherein R1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of dysautonomia, bladder dysfunction, hearing impairment, bone disease and the like.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: March 3, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Asae Shintani
  • Tgf-beta superfamily production/secretion promoter
    Publication number: 20040142988
    Abstract: The present invention provides a TGF-&bgr; superfamily production/secretion promoter comprising a compound represented by the formula 1
    Type: Application
    Filed: December 16, 2003
    Publication date: July 22, 2004
    Inventors: Yasuo Sugiyama, Masatoshi Hazama, Asae Shintani